Cancers最新文献

{"title":"Work Ability in Patients with Chronic Myeloid Leukemia: A Danish Nationwide Cohort Study.","authors":"Eva Futtrup Maksten, Jonas Faartoft Jensen, Gitte Thomsen, Ditte Rechter Zenas, Maren Poulsgaard Jørgensen, Lene Udby, Kirsten Fonager, Marianne Tang Severinsen","doi":"10.3390/cancers17091585","DOIUrl":"10.3390/cancers17091585","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Patients with chronic myeloid leukemia (CML) have a long life expectancy due to modern treatment. However, treatment may have adverse effects that hamper work ability. <b>Methods</b>: Patients aged 25-60 years diagnosed in 2002-2020 were included in this nationwide matched cohort study examining work ability from diagnosis (index date), including the need for permanent disability compensation (flexible job or disability pension). Each patient was matched 1:5 on sex, birth year, and level of comorbidity with citizens from the general Danish population without CML. The risks of requiring flexible job and disability pension were calculated by cause-specific hazard ratios (HRs) using Cox proportional hazards regression, and the Aalen-Johansen estimator was used to determine cumulative risks. <b>Results</b>: A total of 489 patients with CML and 2445 matched comparators were included. The median age was 46 years, and males comprised 59.5% of the cohort. Matched comparators were more likely to work at index date and 1, 3, 5, and 10 years after the index date (<i>p</i> < 0.001). The HRs of requiring both flexible job (HR 8.7 (95% confidence interval (CI): 6.1;12.2, <i>p</i> < 0.001)) and disability pension (HR 3.7 (95% CI: 2.8;4.9, <i>p</i> < 0.001)) were higher among patients diagnosed with CML compared to matched comparators. The cumulative risk of requiring flexible job and disability pension also increased in patients with CML compared to matched comparators (<i>p</i> < 0.001). <b>Conclusions</b>: Patients with CML have a reduced work ability compared to the general population. More research is needed to determine the cause of their loss of ability to work.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12072068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Language Processing of Radiology Reports to Assess Survival in Patients with Advanced Melanoma.","authors":"Jeeban P Das, Jordan Eichholz, Varadan Sevilimedu, Natalie Gangai, Danny N Khalil, Michael A Postow, Richard K G Do","doi":"10.3390/cancers17091595","DOIUrl":"10.3390/cancers17091595","url":null,"abstract":"<p><p><b>Background/Objectives</b>: To use natural language processing (NLP) to extract large-scale data from the CT radiology reports of patients with advanced melanoma treated with immunotherapy and to determine whether liver metastases affect survival. <b>Methods</b>: Patient criteria (M1 disease subclassified into M1a, M1b, or M1c) as well as alternative criteria (M1 with advanced melanoma, imaged with CT chest, abdomen, and pelvis from July 2014-March 2019) were included retrospectively. NLP was used to identify metastases from CT reports, and then patients were classified according to American Joint Committee on Cancer (AJCC) staging disease subclassified into M1L+ or M1L-, indicating whether liver metastases were present or not). Statistical analysis included constructing Kaplan-Meier survival curves and calculating hazard ratios (HRs). <b>Results</b>: 2239 patients were included (mean age, 63 years). Whether using AJCC or alternative criteria, overall survival (OS) was poorest for M1L+ (entire cohort median OS, 0.69 years [95% CI: 0.60-0.82]; immunotherapy cohort median OS, 1.4 years [95% CI: 0.92-2.0]) compared to M1L- (entire cohort median OS, 1.8 years [95% CI: 1.4-2.2]; immunotherapy cohort median OS; M1L-, 2.9 years [95% CI: 2.3-3.9]). The median HR for M1L+ (median HR, 5.35 [95% CI: 4.59-6.24]) was higher than that for M0 (<i>p</i> < 0.001). The median HR for M1L+ (median HR, 2.13 [95% CI: 1.65-2.64]) was higher than that for M0 (<i>p</i> < 0.01). <b>Conclusions</b>: Patients with advanced melanoma, particularly those with liver metastases, demonstrated inferior survival, even when treated with immunotherapy.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Turchi et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. <i>Cancers</i> 2023, <i>15</i>, 5038.","authors":"Laurent Turchi, Nathalie Sakakini, Gaelle Saviane, Béatrice Polo, Mirca Saras Saurty-Seerunghen, Mathieu Gabut, Corine Auge Gouillou, Vincent Guerlais, Claude Pasquier, Marie Luce Vignais, Fabien Almairac, Hervé Chneiweiss, Marie-Pierre Junier, Fanny Burel-Vandenbos, Thierry Virolle","doi":"10.3390/cancers17091583","DOIUrl":"10.3390/cancers17091583","url":null,"abstract":"<p><p>In the original publication [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12072141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emotional Functioning in Long-Term Breast Cancer Survivors: A Cross-Sectional Study on Its Influence and Key Predictors.","authors":"Francisco Álvarez-Salvago, Sandra Atienzar-Aroca, Clara Pujol-Fuentes, Maria Figueroa-Mayordomo, Cristina Molina-García, Palmira Gutiérrez-García, Jose Medina-Luque","doi":"10.3390/cancers17091574","DOIUrl":"10.3390/cancers17091574","url":null,"abstract":"<p><p><b>Background/Objectives</b>: This study aimed to analyze the relationship between emotional functioning and health status in long-term breast cancer survivors (LTBCSs). Additionally, it sought to identify factors that could influence emotional functioning in this population at least five years after cancer diagnosis. <b>Methods</b>: This cross-sectional observational study included 80 LTBCSs, classified into the following two groups, according to their emotional functioning: those experiencing psychological distress (≤90) and those with satisfactory psychological well-being (≥91). The study examined various factors at least five years post-diagnosis, including sociodemographic and clinical characteristics, health-related quality of life (HRQoL), mood state, self-perceived physical fitness, physical activity (PA) level, pain, and cancer-related fatigue (CRF). ANOVA, Mann-Whitney U, and Chi-square tests were conducted, along with correlation and multiple regression analysis. Effect sizes were calculated using Cohen's <i>d</i>. <b>Results</b>: Among the 80 LTBCSs, 47.50% reported psychological distress, while 52.50% maintained satisfactory psychological well-being. Participants in the psychological distress group exhibited significantly poorer HRQoL, lower mood, and reduced self-perceived physical fitness, as well as higher levels of physical inactivity, pain, and CRF (<i>p</i> < 0.05). Regression analysis revealed that \"role functioning\" (β = 0.59; <i>p</i> < 0.01), \"cognitive functioning\" (β = 0.26; <i>p</i> < 0.01), \"self-perceived physical fitness\" (β = 0.20; <i>p</i> = 0.02), and \"sadness-depression\" (β = 0.18; <i>p</i> = 0.04) were significant predictors of emotional functioning (r² adjusted = 0.642). <b>Conclusions</b>: These results emphasize the association between emotional functioning and health status in LTBCSs. Role functioning, cognitive functioning, self-perceived physical fitness, and mood state were identified as relevant factors influencing emotional well-being in this population. Considering these relationships, integrating psychological and physical assessments into survivorship care could support the early detection of at-risk individuals. This approach could also guide interventions to improve their long-term well-being and HRQoL.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Local Prostate Cancer Recurrence from PET/CT Scans Using Deep Learning.","authors":"Marko Korb, Hülya Efetürk, Tim Jedamzik, Philipp E Hartrampf, Aleksander Kosmala, Sebastian E Serfling, Robin Dirk, Kerstin Michalski, Andreas K Buck, Rudolf A Werner, Wiebke Schlötelburg, Markus J Ankenbrand","doi":"10.3390/cancers17091575","DOIUrl":"10.3390/cancers17091575","url":null,"abstract":"<p><p><b>Background:</b> Prostate cancer (PC) is a leading cause of cancer-related deaths in men worldwide. PSMA-directed positron emission tomography (PET) has shown promising results in detecting recurrent PC and metastasis, improving the accuracy of diagnosis and treatment planning. To evaluate an artificial intelligence (AI) model based on [¹⁸F]-prostate specific membrane antigen (PSMA)-1007 PET datasets for the detection of local recurrence in patients with prostate cancer. <b>Methods:</b> We retrospectively analyzed 1404 [¹⁸F]-PSMA-1007 PET/CTs from patients with histologically confirmed prostate cancer. Artificial neural networks were trained to recognize the presence of local recurrence based on the PET data. First, the hyperparameters were optimized for an initial model (model A). Subsequently, the bladder was localized using an already published model and a model (model B) was trained only on a 20 cm cube around the bladder. Finally, two separate models were trained on the same section depending on the prostatectomy status (model C (post-prostatectomy) and model D (non-operated)). <b>Results:</b> Model A achieved an accuracy of 56% on the validation data. By restricting the region to the area around the bladder, Model B achieved a validation accuracy of 71%. When validating the specialized models according to prostatectomy status, model C achieved an accuracy of 77% and model D an accuracy of 77%. All models achieved accuracies of almost 100% on the training data, indicating overfitting. <b>Conclusions:</b> For the presented task, 1404 examinations were insufficient to reach an accuracy of over 90% even when employing data augmentation, including additional metadata and performing automated hyperparameter optimization. The low F1-score and AUC values indicate that none of the presented models produce reliable results. However, we will facilitate future research and the development of better models by openly sharing our source code and all pre-trained models for transfer learning.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Evolving Landscape of Radiomics in Gliomas: Insights into Diagnosis, Prognosis, and Research Trends.","authors":"Mehek Dedhia, Isabelle M Germano","doi":"10.3390/cancers17091582","DOIUrl":"10.3390/cancers17091582","url":null,"abstract":"<p><p>Gliomas are the most prevalent and aggressive form of primary brain tumors. The clinical challenge in managing patients with this disease revolves around the difficulty of diagnosis, both at onset and during treatment, and the scarcity of prognostic outcome indicators. Radiomics involves the extraction of quantitative features from medical images with the help of artificial intelligence, positioning it as a promising tool to be integrated into the care of glioma patients. Using data from 52 studies and 12,482 patients over two years, this review explores how radiomics can enhance the initial diagnosis of gliomas, especially helping to differentiate treatment stages that may be difficult for the human eye to do otherwise. Radiomics has also been able to identify patient-specific tumor molecular signatures for targeted treatments without the need for invasive surgical biopsy. Such an approach could lead to earlier interventions and more precise individualized therapies that are tailored to each patient. Additionally, it could be integrated into clinical practice to improve longitudinal diagnosis during treatment and predict tumor recurrence. Finally, radiomics has the potential to predict clinical outcomes, helping both patients and providers set realistic expectations. While this field is continuously evolving, future research should conduct such studies in larger, multi-institutional cohorts to enhance generalizability and applicability in clinical practice and focus on combining radiomics with other modalities to improve its predictive accuracy and clinical utility.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives.","authors":"Susana Cedres, Augusto Valdivia, Ilaria Priano, Pedro Rocha, Patricia Iranzo, Nuria Pardo, Alex Martinez-Marti, Enriqueta Felip","doi":"10.3390/cancers17091581","DOIUrl":"10.3390/cancers17091581","url":null,"abstract":"<p><p>Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy have improved survival in PM patients, but overall survival remains poor. Molecular analysis of PM patients has shown that most alterations occur in tumor suppressor genes, with BAP1 being the most frequently affected. Patients with germline BAP1 mutations have been reported to have a better prognosis, but this is not observed in those with somatic mutations. Interest in developing drugs targeting patients with BAP1 loss has led to several phase II studies in recent years. Unfortunately, initial results have not been very promising. In this review, we conclude that, at this time, with the contradictory results from studies and the limited number of patients evaluated, BAP1, the most commonly altered gene in PM, is not yet suitable for use in clinical practice as a prognostic or predictive factor. Future studies are needed to establish the prognostic or predictive value of BAP1.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Particle Therapy to Overcome Cancer Radiation Resistance: \"ARCHADE\" Consortium Updates in Radiation Biology.","authors":"Samuel Valable, Mathieu Césaire, Kilian Lecrosnier, Antoine Gilbert, Mihaela Tudor, Guillaume Vares, Dounia Houria Hamdi, Ousseynou Ben Diouf, Thao Nguyen Pham, Julie Coupey, Juliette Thariat, Paul Lesueur, Elodie Anne Pérès, Juliette Aury-Landas, Zacharenia Nikitaki, Siamak Haghdoost, Carine Laurent, Jean-Christophe Poully, Jacques Balosso, Myriam Bernaudin, Diana I Savu, François Chevalier","doi":"10.3390/cancers17091580","DOIUrl":"10.3390/cancers17091580","url":null,"abstract":"<p><p>Radiation therapy is a medical treatment that uses high doses of radiation to kill or damage cancer cells. It works by damaging the DNA within the cancer cells, ultimately causing cell death. Radiotherapy can be used as a primary treatment, adjuvant treatment in combination with surgery or chemotherapy or palliative treatment to relieve symptoms in advanced cancer stages. Radiation therapy is constantly improving in order to enhance the effect on cancer cells and reduce the side effects on healthy tissues. Our results clearly demonstrate that proton therapy and, even more, carbon ion therapy appear as promising alternatives to overcome the radioresistance of various tumors thanks to less dependency on oxygen and a better ability to kill cancer stem cells. Interestingly, hadrons also retain the advantages of radiosensitization approaches. These data confirm the great ability of hadrons to spare healthy tissue near the tumor via various mechanisms (reduced lymphopenia, bystander effect, etc.). Technology and machine improvements such as image-guided radiotherapy or particle therapies can improve treatment quality and efficacy (dose deposition and biological effect) in tumors while increasingly sparing healthy tissues. Radiation biology can help to understand how cancer cells resist radiation (hypoxia, DNA repair mechanisms, stem cell status, cell cycle position, etc.), how normal tissues may display sensitivity to radiation and how radiation effects can be increased with either radiosensitizers or accelerated particles. All these research topics are under investigation within the ARCHADE research community in France. By focusing on these areas, radiotherapy can become more effective, targeted and safe, enhancing the overall treatment experience and outcomes for cancer patients. Our goal is to provide biological evidence of the therapeutic advantages of hadrontherapy, according to the tumor characteristics. This article aims to give an updated view of our research in radiation biology within the frame of the French \"ARCHADE association\" and new perspectives on research and treatment with the C400 multi-ions accelerator prototype.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression?","authors":"Julia Drewa, Katarzyna Lazar-Juszczak, Jan Adamowicz, Kajetan Juszczak","doi":"10.3390/cancers17091576","DOIUrl":"10.3390/cancers17091576","url":null,"abstract":"<p><strong>Introduction: </strong>GLP-1 receptor agonists are valuable therapeutic agents for managing obesity and type 2 diabetes. The link between prostate cancer and obesity was described. The modulation of incretin hormone-dependent pathways may decrease the prostate cancer aggressiveness and progression.</p><p><strong>Objectives: </strong>The purpose of this study was to review and summarize the literature on the role of GLP-1 agonists in prostate cancer.</p><p><strong>Material & methods: </strong>We performed a scoping literature review of PubMed from January 2002 to February 2025. Search terms included \"glucagon-peptide like 1\", \"incretin hormone\", \"GLP-1 receptor agonist\", and \"prostate cancer\". Secondary search involved reference lists of eligible articles. The key criterion was to identify studies that included GLP-1 receptor, incretin hormones, GLP-1 receptor agonists, and their role in prostate cancer development.</p><p><strong>Results: </strong>77 publications were selected for inclusion in this review. The studies contained in publications allowed us to summarize the data on the role of GLP-1 receptor and it's agonists in prostate cancer biology and development. The following review aims to discuss and provide information about the role of incretin hormones in prostate cancer pathogenesis and its clinical implication in patients with prostate cancer.</p><p><strong>Conclusion: </strong>Incretin hormone-dependent pathways play an important role in prostate cancer pathogenesis. Moreover, GLP-1 receptor agonists seems to be a promising therapeutical agents when it comes to finding new therapies in patients with more aggressive and/or advanced stages of prostate cancer.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Comorbidities in Lung Cancer Patients and Survival.","authors":"Alessandra Buja, Marcello Di Pumpo, Massimo Rugge, Manuel Zorzi, Federico Rea, Ilaria Pantaleo, Giovanna Scroccaro, Pierfranco Conte, Leonardo Rigon, Giorgio Arcara, Giulia Pasello, Valentina Guarneri","doi":"10.3390/cancers17091577","DOIUrl":"10.3390/cancers17091577","url":null,"abstract":"<p><strong>Introduction: </strong>Comorbidities affect diagnosis and treatments in cancer patients. This study explores the prevalence and patterns of comorbidities in non-small cell lung cancer (NSCLC) patients and their association with survival.</p><p><strong>Materials and methods: </strong>This retrospective population-based cohort study included 1674 incident NSCLC patients. Comorbidities were classified based on the ICD-9-CM system, with 13 disease categories analyzed. Patients with more than two comorbidities were classified into three mutually exclusive and exhaustive latent classes (Latent Class Analysis [LCA]). The optimal number of latent classes was determined by applying the Akaike Information Criterion. Cox regression models were run to assess overall and cancer-specific mortality, adjusting for the comorbidity groups, sex, age, and stage at diagnosis.</p><p><strong>Results: </strong>In 1674 NSCLC patients, the most prevalent medical conditions were respiratory (35.8%) and cardiovascular (33.5%). The Cox regression showed that even one comorbidity is associated with an increased hazard of overall mortality (HR = 1.33, 95%CI: 1.11-1.59, <i>p</i> = 0.002). LCA-derived Class-1 (cardiovascular-respiratory and endocrine) reported HR = 1.74 (95%CI: 1.39-2.17, <i>p</i> < 0.001), Class-2 (multi-organ) HR = 1.44 (95%CI: 1.18-1.77, <i>p</i> < 0.001), and Class-3 (socio-multifactorial-neuro) HR = 1.62 (95%CI: 1.36-1.93, <i>p</i> < 0.001). Instead, in patients with one comorbidity, NSCLC-specific mortality showed no significant trend towards increased risk (HR = 1.17, 95%CI: 1.00-1.43, <i>p</i> = 0.114). Significant associations emerged between NSCLC-specific mortality and LCA-classes: Class-1: HR = 1.49 (95%CI: 1.20-1.91, <i>p</i> = 0.001); Class-2 HR = 1.25 (95%CI: 1.0-1.57 <i>p</i> = 0.048); and Class-3: HR = 1.23 (95%CI: 1.00-1.48, <i>p</i> = 0.035).</p><p><strong>Conclusions: </strong>The adverse impact of comorbidities on NSCLC-specific mortality requires their inclusion as risk factors in cancer treatment and prognosis.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}